
    
      A phase 3, multicenter, randomized study to evaluate the substitution of MarqiboÂ®
      (Vincristine Sulfate Liposomes Injection, VSLI) for standard Vincristine Sulfate Injection
      (VSI) in the induction, intensification, and maintenance phases of combination chemotherapy
      in the treatment of subjects >or= 60 years old with newly diagnosed acute lymphoblastic
      leukemia (ALL).
    
  